HIV-1 vaccines and co-infection.

Abstract

Vaccines are an economically efficient means of controlling viral infections, and it is likely that a vaccine against HIV-1 will be the most effective way of controlling the global AIDS crisis. However, an effective vaccine has not yet been attainable and in developing countries co-infection with protozoa and other chronic diseases adds another level of complexity to the design of an HIV-1 vaccine. Helminthic and protozoan infections can result in a constant state of immune activation that is characterised by a dominant T helper (Th)2 type of cytokine profile. Such an immune profile is likely to have an adverse impact on the efficacy of an HIV-1 vaccine CD8 cellular immune response and the corresponding Th1 cytokines that are most likely to be important for clearing viral infections.

• Authors: Tara M Robinson, Jean D Boyer
• Journal: Expert opinion on biological therapy (Expert Opin Biol Ther) Vol. 4 Issue 9 Pg. 1483-92 (Sep 2004) ISSN: 1744-7682 [Electronic] England
• PMID: 15335315 (Publication Type: Journal Article, Review)

Chemical References

• AIDS Vaccines
• Cytokines
• HIV Antibodies

Topics

• AIDS Vaccines (immunology)
• Animals
• Antigen Presentation
• B-Lymphocytes (immunology)
• CD8-Positive T-Lymphocytes (immunology)
• Comorbidity
• Cytokines (immunology, metabolism)
• HIV Antibodies (immunology)
• HIV Infections (complications, immunology, prevention & control)
• HIV-1 (immunology)
• Helminthiasis (complications, immunology)
• Humans
• Immunity, Cellular
• Lymphocyte Count
• Mice
• Mice, Inbred C57BL
• Mice, Transgenic
• Models, Immunological
• Parasitic Diseases (complications, immunology)
• Protozoan Infections (complications, immunology)
• Th1 Cells (immunology, metabolism)
• Th2 Cells (immunology, metabolism)